EFFICACY OF MONOTHERAPY VERSUS COMBINATION THERAPY IN MODERATE HYPERTENSION

Authors

  • ABID A. KHAN
  • MAIMOONA INAYAT

DOI:

https://doi.org/10.47144/phj.v37i1-2.75

Keywords:

VERSUS COMBINATION

Abstract

This prospective study was conducted to ascertain the difference in efficacy of a long term ACE inhibitor,
Ramipril, used alone and in combination with a dihydropyridine calcium antagonist, amlodipine, in
moderate hypertension. The patients were free from long term complications of hypertension. This study
included 60 patients aged 25-62 years (42males , 18 females ) with essential hypertension, stage II i.e. systolic
B.P ³160 mmHg and diastolic B.P³100mmHg (JNCVI ). Two groups of patients were formed, group A
included patients treated with Ramipril alone and group B included patients treated with combination of
Ramipril and amlodipine over a period of six weeks. The study showed a prominent decline in blood pressure
of patients in both groups, however target blood pressure was achieved and sustained more effectively in
group B .
It is concluded that in order to obtain a more stable drop in blood pressure, combination therapy is more
beneficial both in efficacy and cost effectiveness than monotherapy.

Downloads

Download data is not yet available.

Downloads

How to Cite

1.
KHAN AA, INAYAT M. EFFICACY OF MONOTHERAPY VERSUS COMBINATION THERAPY IN MODERATE HYPERTENSION. Pak Heart J [Internet]. 2012May12 [cited 2024Nov.23];37(1-2). Available from: https://pakheartjournal.com/index.php/pk/article/view/75

Issue

Vol. 37 No. 1-2 (2004): Pakistan Heart Journal

Section

Original Article

License

When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.

Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/